Figure 1.

The development of a GPCR-directed theranostic peptide radioligand from bench to patient. The peptide conjugate is synthesized and radiolabeled and its biological profile evaluated first in cells and tumor-bearing mice expressing the target. Best candidates are selected for translation in humans. Labeling with a gamma emitter allows for SPECT imaging whereas a positron emitter enables PET imaging. Both techniques will indicate patients eligible for radiotherapy with an alpha, beta or Auger electron emitter to eradicate tumor cells, according to precision medicine principles.